Studying PT217 for neuroendocrine cancers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of neuroendocrine cancer (like small cell lung cancer) that has spread and cannot be removed with surgery.
- You must have tried at least one standard treatment (like chemotherapy) for your cancer, or standard treatment is not available or not right for you.
- You must be able to provide a sample of your tumor (either from a recent biopsy or an older sample) for testing.
- You must be in good enough health to get out of bed and take care of yourself (ECOG score 0 or 1).
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of an immunotherapy drug (QL1706), a targeted therapy (lenvatinib), and chemotherapy for people with advanced neuroendocrine carcinoma that started outside the lungs. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
This trial tests a new drug (LBL-024) combined with standard chemo as a first treatment for a rare and fast-growing neuroendocrine cancer (EP-NEC) that started outside the lungs. It may offer a new option for people whose cancer has spread and who haven't had treatment yet.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of immunotherapy (benmelstobart), a targeted therapy (anlotinib), and chemotherapy as the first treatment for advanced neuroendocrine cancers that started in the lung or gut. It aims to see if this combo works better than standard chemo alone.
Hear when a new Neuroendocrine Prostate Cancer (NEPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.